Altimmune To Announce Year End 2020 Financial Results on February 25, 2021

Altimmune plans to report its full year 2020 financial results on February 25, 2021.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Altimmune plans to report its full year 2020 financial results on February 25, 2021. The company will hold a conference call at 8:30 AM ET to discuss these results and provide a business update. Altimmune focuses on developing intranasal vaccines and immune modulating therapies, with a diverse pipeline including products for COVID-19, anthrax, influenza, and liver disease. The company's offerings include AdCOVID™, NasoShield™, NasoVAX™, T-COVID™, ALT-801, and HepTcell™.

Positive

Upcoming report on full year 2020 financial results expected to provide insights into company performance.
Diverse pipeline with potential high-impact intranasal vaccines and therapies for significant health issues.

Negative

None.

Argus Session date unavailable

-2.04% session move Open Argus

Details

News Market Reaction – ALT

The recorded move for ALT in the trading session of this news was -2.04%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

02/22/2021 - 04:30 PM EST

GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25^th, 2021.

Altimmune management will host a conference call for investors beginning at 8:30 am ET on Thursday, February 25^th, 2021 to discuss financial results and provide a business update.

Conference Call Information:

Date:	Thursday, February 25, 2021
Time:	8:30 am Eastern Time
Domestic Dial-in:	877-423-9813
International Dial-in:	201-689-8573
Conference ID:	13716171
Webcast:	http://public.viavid.com/index.php?id=143423

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Investor & Media Contacts:

Will Brown	Stacey Jurchison
Chief Financial Officer	Sr. Dir, Investor Relations
Phone: 240-654-1450	Phone : 410-474-8200
wbrown@altimmune.com	sjurchison@altimmune.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Altimmune report its financial results?

Altimmune will report its full year 2020 financial results on February 25, 2021.

What time is the Altimmune conference call?

The conference call will start at 8:30 AM ET on February 25, 2021.

How can I access the Altimmune conference call?

You can access the conference call via the domestic dial-in number 877-423-9813 or the international dial-in number 201-689-8573.

What is Altimmune's focus in biopharmaceuticals?

Altimmune focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease.

Altimmune To Announce Year End 2020 Financial Results on February 25, 2021